Edition:
India

ARCA Biopharma Inc (ABIO.OQ)

ABIO.OQ on NASDAQ Stock Exchange Capital Market

6.77USD
1:30am IST
Change (% chg)

$-0.01 (-0.15%)
Prev Close
$6.78
Open
$6.79
Day's High
$6.83
Day's Low
$6.65
Volume
131,352
Avg. Vol
361,354
52-wk High
$22.00
52-wk Low
$2.21

Select another date:

Fri, Jul 3 2020

BRIEF-ARCA Biopharma Files May Offer & Sell Shares Of Common Stock Of Up To $7.6 Mln

* ARCA BIOPHARMA FILES TO SAY MAY OFFER & SELL SHARES OF COMMON STOCK OF UP TO $7.6 MILLION THROUGH JONESTRADING - SEC FILING Source text (https://bit.ly/2BAX0a2) Further company coverage:

BRIEF-Cue Biopharma Provides Update On Ongoing Phase 1 Trial Evaluating CUE-101 In Metastatic Head And Neck Cancer

* CUE BIOPHARMA PROVIDES UPDATE ON ONGOING PHASE 1 TRIAL EVALUATING CUE-101 IN RECURRENT/METASTATIC HEAD AND NECK CANCER

BRIEF-Sabby Management Llc Reports 9.99% Passive Stake In Arca Biopharma As Of June 1

* SABBY MANAGEMENT LLC REPORTS 9.99% PASSIVE STAKE IN ARCA BIOPHARMA AS OF JUNE 1 - SEC FILING Source text - https://bit.ly/2AtEH5Q Further company coverage:

BRIEF-ARCA Biopharma Announces $9.4 Mln Registered Direct Offering

* ARCA BIOPHARMA ANNOUNCES $9.4 MILLION REGISTERED DIRECT OFFERING

BRIEF-ARCA Biopharma Announces AB201 Development Program For Treatment Of Covid-19 Associated Coagulopathy

* ARCA BIOPHARMA ANNOUNCES AB201 DEVELOPMENT PROGRAM FOR TREATMENT OF COVID-19 ASSOCIATED COAGULOPATHY

BRIEF-Arca Biopharma Files For Mixed Shelf Of Upto $75 Million

* ARCA BIOPHARMA INC FILES FOR MIXED SHELF OF UPTO $75 MILLION - SEC FILING Source: (https://bit.ly/2L9gGTF) Further company coverage:

BRIEF-ARCA Biopharma Reports Q1 Loss Per Share $0.83

* ARCA BIOPHARMA ANNOUNCES FIRST QUARTER 2020 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

BRIEF-Arca Biopharma Files Prospectus For Offering Up To $15 Million Of Shares Of Common Stock And Warrants

* ARCA BIOPHARMA INC FILES PROSPECTUS FOR OFFERING UP TO $15 MILLION OF SHARES OF COMMON STOCK AND WARRANTS - SEC FILING Source: (https://bit.ly/39452Uy) Further company coverage:

BRIEF-Arca Biopharma Says FDA Issued Special Protocol Assessment Agreement For Single Phase 3 Clinical Trial For Precision-AF

* ARCA BIOPHARMA ANNOUNCES FISCAL YEAR 2019 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

Select another date: